AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02461264
Drug: Two packed red blood cells Transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00269789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03440892
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: folate antagonist
Trial: NCT01638663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Unikalk 1 pr day for 1 day
Trial: NCT04085419
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid 5 mg intravenously once a year
Trial: NCT00604019
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine 5-20 mcg/kg/min to pre-determined max of 20
Trial: NCT00604019
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
Trial: NCT04189367
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks
Trial: NCT00952302
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
Trial: NCT02383108
Drug: DTG +DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
Trial: NCT00952302
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
Trial: NCT05042024
Drug: Oral L-arginine aspartate administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Trial: NCT05042024
Drug: Oral L-ornithine aspartate administration
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Trial: NCT02529995
Drug: AZD9291 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Trial: NCT02529995
Drug: AZD9291 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Trial: NCT03239483
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal HEC placebo gel; administered rectally
Trial: NCT00101010
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 IVPB on day 1
Trial: NCT00101010
Drug: Pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
Trial: NCT02706717
Drug: Visbiome Extra Strength
RxNorm normalized name: Visbiome Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Trial: NCT02706717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Trial: NCT03737240
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
Trial: NCT01893229
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine is used as a mood stabiliser
Trial: NCT01179672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
Trial: NCT04216251
Drug: AMR101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
Trial: NCT00835770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken to maintain the blind in the 240 mg BID treatment group.
Trial: NCT00226538
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00226538
Drug: Diclophenac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03222323
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (saline) is administered perineurally in all but the perineural group.
Trial: NCT01317758
Drug: AS03 Adjuvant
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
Trial: NCT00998985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, orally, once a day for 7 days
Trial: NCT02280525
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.
Trial: NCT00444600
Drug: Sham injection + laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Trial: NCT00333931
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00620997
Drug: Proparacaine drops 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical, 0.05% drops, PRN continuously for up to 7 days
Trial: NCT00620997
Drug: saline drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline drops continuously PRN for up to 7 days
Trial: NCT00139672
Drug: PD-217,014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00477035
Drug: CIK cells
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x10e8 cells/kg
Trial: NCT00477035
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/kg
Trial: NCT03320434
Drug: PRT-2761 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six drops in each eye over a 17 day period.
Trial: NCT03320434
Drug: PRT-2761 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six drops in each eye over a 17 day period.
Trial: NCT03320434
Drug: PRT-2761 0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six drops in each eye over a 17 day period.
Trial: NCT02561039
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
Trial: NCT02637167
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
Trial: NCT00923962
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-40 microgram/minute
Trial: NCT01045486
Drug: ATP mixed probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
Trial: NCT01045486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
Trial: NCT01640002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
Trial: NCT03099304
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Trial: NCT03876717
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo tablets over-encapsulated with DB caps AAA
Trial: NCT01718288
Drug: Standard Treatment (aspirin.....),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids
Trial: NCT01428297
Drug: BPR277 ointment (controlled application)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428297
Drug: Placebo (Vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428297
Drug: BPR277 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428297
Drug: BPR277
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00126646
Drug: BL22 immunotoxin
RxNorm normalized name: hepatitis B immunoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00503750
Drug: ABI-007 (Abraxane)
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
Trial: NCT04068207
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Minocycline 100mg po per day for 12 months
Trial: NCT02589340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill
Trial: NCT02489435
Drug: VM-1500
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VM-1500
Trial: NCT02489435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02971423
Drug: ETX2514
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02971423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo infusion
Trial: NCT01251315
Drug: Placebo low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Trial: NCT01251315
Drug: N Acetyl cysteine, 600mg (low dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
Trial: NCT01708798
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01708798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01251315
Drug: Placebo (high dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Trial: NCT01251315
Drug: N Acetyl cysteine, 1200mg (high dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
Trial: NCT01251315
Drug: FT061452, 6000mg high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
Trial: NCT02514278
Drug: Neoadjuvant chemotherapy Folfirinox, 4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2
Trial: NCT02514278
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1600 mg/m2 daily 5 days/7
Trial: NCT00405535
Drug: glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01444417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by subcutaneous injection
Trial: NCT00814905
Drug: ampicillin gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
Trial: NCT00814905
Drug: Ampicillin gentamicin clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
Trial: NCT00814905
Drug: ampicillin gentamicin clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
Trial: NCT02837900
Drug: TPX-100 200 mg 4 times weekly for 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ea. subject will received active TPX-100 200mg in the Left knee
Trial: NCT02837900
Drug: TPX-100 200 mg 4 times weekly for 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPX-100 100mg Right
Trial: NCT03094182
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
Trial: NCT01831700
Drug: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Trial: NCT01831700
Drug: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Trial: NCT03628040
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be injected in the erector spinae plane
Trial: NCT00388661
Drug: Melatonin tablet 3 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin tablet 3 mg once daily
Trial: NCT00388661
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00237770
Drug: N-Nitro L-arginine-methylester (L-NAME)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Trial: NCT00026234
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00989001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT00818805
Drug: Placebo (Olopatadine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop in contralateral eye
Trial: NCT00818805
Drug: Placebo (Tranilast)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop in contralateral eye
Trial: NCT01179334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks
Trial: NCT02626299
Drug: Docosahexaenoic acid - 800mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
Trial: NCT02626299
Drug: Docosahexaenoic acid - 200mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive 1-capsule containing 200 mg DHA/d.
Trial: NCT02352090
Drug: Ethinyl estradiol / dienogest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally for 9 weeks, continuous use
Trial: NCT02352090
Drug: Estradiol valerate / dienogest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally for 9 weeks, continuous use
Trial: NCT00193128
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
Trial: NCT01654328
Drug: Isotonic saline intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
Trial: NCT00468910
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02655029
Drug: Perindopril/Indapamide/Amlodipine fixed dose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose selection is based on investigators management.
Trial: NCT03908333
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25, 37.5, 56.25 or 75 grams/m2
Trial: NCT01576952
Drug: ISV-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac in DuraSite
Trial: NCT01847872
Drug: IPV IM Device
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01847872
Drug: IPV ID Device
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00111709
Drug: Comparator: placebo / Duration of Treatment - 1 day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00838253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo continuous i.v. infusion for 24 hours
Trial: NCT04673214
Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
Trial: NCT00529659
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily, 6 month treatment period
Trial: NCT01823133
Drug: rosuvastatin only
RxNorm normalized name: Rosuvastatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20mg qd on day 1\~7
Trial: NCT01823133
Drug: gemigliptin and rosuvastatin
RxNorm normalized name: gemigliptin and rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
Trial: NCT01503749
Drug: G-colony stimulating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
Trial: NCT04673214
Drug: Azithromycin / Ribaroxaban / Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
Trial: NCT04321031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03876210
Drug: PK101-001, PK101-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coadministration
Trial: NCT03684863
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: observation